VTGN Stock Overview A biopharmaceutical company, engages in the development and commercialization of therapies for psychiatric and neurological disorders. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Vistagen Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Vistagen Therapeutics Historical stock prices Current Share Price US$3.03 52 Week High US$5.74 52 Week Low US$2.22 Beta 0.78 1 Month Change 20.72% 3 Month Change 0% 1 Year Change -44.40% 3 Year Change -94.20% 5 Year Change -86.07% Change since IPO -99.79%
Recent News & Updates
New minor risk - Shareholder dilution Nov 22
We're Hopeful That Vistagen Therapeutics (NASDAQ:VTGN) Will Use Its Cash Wisely Nov 15
Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 10
Vistagen to Present At the 2024 Neuroscience Education Institute Congress Nov 05
Vistagen Therapeutics, Inc. to Report Q2, 2025 Results on Nov 07, 2024 Nov 01
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Sep 26 See more updates
New minor risk - Shareholder dilution Nov 22
We're Hopeful That Vistagen Therapeutics (NASDAQ:VTGN) Will Use Its Cash Wisely Nov 15
Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 10
Vistagen to Present At the 2024 Neuroscience Education Institute Congress Nov 05
Vistagen Therapeutics, Inc. to Report Q2, 2025 Results on Nov 07, 2024 Nov 01
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Sep 26
Consensus revenue estimates increase by 161% Aug 20
First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 15
Vistagen Therapeutics, Inc. to Report Q1, 2025 Results on Aug 13, 2024 Aug 06
Full year 2024 earnings: EPS exceeds analyst expectations Jun 13
New minor risk - Market cap size Jun 11
Vistagen Therapeutics, Inc. to Present At the 2024 American Society of Clinical Psychopharmacology Conference May 24
Vistagen Announces Positive Results from Phase 2A Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue Apr 26
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 Apr 02
Consensus EPS estimates upgraded to US$1.60 loss, revenue downgraded Feb 20
Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Feb 14 Vistagen Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Feb 14
Vistagen Therapeutics, Inc. to Report Q3, 2024 Results on Feb 13, 2024 Feb 07
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain Dec 27
Vistagen Therapeutics, Inc. to Report Q2, 2024 Results on Nov 09, 2023 Nov 07
Vistagen Therapeutics, Inc. Appoints Joshua Prince as the Chief Operating Officer Oct 28
New major risk - Shareholder dilution Oct 06
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder Sep 13
Vistagen Appoints Cindy Anderson as Chief Financial Officer Aug 23
Vistagen Therapeutics, Inc. Announces Positive Phase 3 Trial Results from Phase 3 Palisade-2 Trial of Rapid-onset Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder (SAD) Aug 11
Vistagen Therapeutics, Inc. to Report Q1, 2024 Results on Aug 10, 2023 Aug 09
New major risk - Share price stability Aug 08
Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder Aug 08
Vistagen Therapeutics, Inc., Annual General Meeting, Sep 25, 2023 Jul 29
Vistagen Therapeutics, Inc. Announces New Mechanism of Action Data from Preclinical Tissue Distribution Study in Laboratory Rats Jul 21
Vistagen Therapeutics, Inc. Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray's Potential Antidepressant Activity Via Peripheral Nasal Neurons Without Entry into the Brain Jul 18
Vistagen Therapeutics, Inc. Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease Jul 14
Vistagen Therapeutics, Inc. Announces Retirement of Jerrold D. Dotson, Chief Financial Officer, Effective on or About August 31, 2023 Jul 10
Vistagen Regains Full Compliance with Nasdaq Listing Requirements Jun 24
Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder Jun 22
Vistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine Jun 14
VistaGen Therapeutics, Inc. Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes Jun 08
Vistagen Provides Nasdaq Compliance Update Jun 07
Forecast to breakeven in 2026 Apr 01
VistaGen Therapeutics, Inc. to Report Q3, 2023 Results on Feb 07, 2023 Feb 07
VistaGen Therapeutics, Inc. (NasdaqCM:VTGN) completed the acquisition of Pherin Pharmaceuticals, Inc. Feb 03
Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder Jan 25
Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety Jan 11
Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder Dec 08
Vistagen Receives FDA "Study May Proceed" Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder Dec 01
VistaGen Therapeutics, Inc. Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease Nov 18
Price target decreased to US$2.82 Nov 16
VistaGen Therapeutics, Inc. to Report Q2, 2023 Results on Nov 10, 2022 Nov 05
VistaGen Therapeutics, Inc., Annual General Meeting, Oct 28, 2022 Oct 20
Vistagen Presents Poster at Psych Congress 2022 Highlighting Effect of PH94B on Nasal Electrogram Responses and Biomarkers of Autonomic Nervous System Activity in Healthy Human Subjects Sep 20
Vistagen Therapeutics, Inc. Announces Completion of an Interim Analysis of PALISADE-2 Sep 09
VistaGen to proceed with phase 3 anxiety nasal spray trial following interim analysis Sep 08
Vistagen Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance of Minimum Bid Price Sep 08
VistaGen Therapeutics, Inc., Annual General Meeting, Oct 14, 2022 Sep 01
CEO & Director recently bought US$103k worth of stock Aug 20
Consensus forecasts updated Aug 18
Forecast to breakeven in 2025 Jul 27
Consensus forecasts updated Jul 23
Price target decreased to US$3.36 Jul 23
Vistagen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug Ph94b Jul 23
VistaGen drops 80% as late-stage study for anxiety therapy fails Jul 22
Consensus revenue estimates fall by 32% Jun 30
No longer forecast to breakeven Jun 25 VistaGen Therapeutics, Inc. Terminates Employment of H. Ralph Snodgrass as President and Chief Scientific Officer
VistaGen Therapeutics, Inc. to Report Fiscal Year 2022 Results on Jun 23, 2022 Jun 18
CEO & Director exercised options to buy US$120k worth of stock. May 17
VistaGen Announces Key Regulatory Update on Ph94b for the Acute Treatment of Social Anxiety Disorder May 06
VistaGen Therapeutics, Inc. Appoints Reid Adler as Chief Legal Officer May 03
Forecast to breakeven in 2025 Apr 27
VistaGen Therapeutics, Inc. to Present Preclinical Data on Lead Candidate PH94B At Upcoming Scientific Congresses Apr 23
Forecast to breakeven in 2025 Apr 15
Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation Apr 10
Forecast to breakeven in 2025 Apr 01
Consensus revenue estimates increase by 17% Feb 17
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Feb 12
VistaGen Therapeutics, Inc. Announces Clinical Trials Update Feb 11
VistaGen Therapeutics, Inc. to Report Q3, 2022 Results on Feb 10, 2022 Feb 08
VistaGen Therapeutics Further Advances PALISADE Phase 3 Program for PH94B in Social Anxiety Disorder with Initiation of PALISADE-2 Sep 14
CFO, VP & Secretary recently sold US$94k worth of stock Sep 09
Consensus forecasts updated Aug 19
Consensus revenue estimates increase to US$1.58m Jul 06
CFO, VP & Secretary exercised options to buy US$304k worth of stock. Jul 06
VistaGen Therapeutics added to Russell 2000 Index Jun 16
VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business Jun 07
VistaGen Therapeutics Initiates PALISADE Phase 3 Trial of PH94B in Social Anxiety Disorder May 27
VistaGen initiates late-stage trial of PH94B in social anxiety disorder May 26
VistaGen names new chief commercial officer May 04
VistaGen Therapeutics, Inc.'s PH10 Nasal Spray Demonstrates Different Mechanism of Action from Benzodiazepines in Preclinical Study Mar 12
New 90-day high: US$2.96 Feb 20
How Does VistaGen Therapeutics' (NASDAQ:VTGN) CEO Salary Compare to Peers? Feb 16
Revenue and earnings beat expectations Feb 13
VistaGen Therapeutics, Inc. Appoints Mark J. Ginski as Senior Vice President, Head of CMC (Chemistry, Manufacturing and Controls) Feb 03
New 90-day high: US$2.32 Jan 13
VistaGen Therapeutics Regains Full Compliance with Nasdaq Listing Requirements Jan 08
VistaGen Therapeutics regains Nasdaq listing compliance Jan 06
VistaGen Therapeutics, Inc. Announces Publication in CNS Spectrums Detailing Proposed Mechanism of Action of Its Investigational Neuroactive Nasal Sprays for Anxiety and Depression Disorders Jan 01
VistaGen Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $57.96 million. Dec 20
VistaGen Therapeutics slumps in after hours trade on underwritten public offering Dec 17 Shareholder Returns VTGN US Biotechs US Market 7D -9.3% -0.1% -0.5% 1Y -44.4% -6.4% 23.2%
See full shareholder returns
Return vs Industry: VTGN underperformed the US Biotechs industry which returned -7% over the past year.
Return vs Market: VTGN underperformed the US Market which returned 23% over the past year.
Price Volatility Is VTGN's price volatile compared to industry and market? VTGN volatility VTGN Average Weekly Movement 8.0% Biotechs Industry Average Movement 11.1% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.6% 10% least volatile stocks in US Market 3.2%
Stable Share Price: VTGN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: VTGN's weekly volatility (8%) has been stable over the past year.
About the Company Vistagen Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for psychiatric and neurological disorders. The company’s product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. It also develops PH80, a hormone-free, odorless, and tasteless synthetic investigational neuroactive pherine nasal spray for the treatment of menopausal hot flashes related vasomotor symptoms and other women’s health indications; PH15, an investigational neuroactive to treat improve psychomotor or cognitive impairment caused by mental fatigue; PH284, an early-stage investigational neuroactive steroid for the treatment of investigational neuroactive pherine nasal spray for the treatments of loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain to treat disorders.
Show more Vistagen Therapeutics, Inc. Fundamentals Summary How do Vistagen Therapeutics's earnings and revenue compare to its market cap? VTGN fundamental statistics Market cap US$84.37m Earnings (TTM ) -US$39.56m Revenue (TTM ) US$876.00k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) VTGN income statement (TTM ) Revenue US$876.00k Cost of Revenue US$0 Gross Profit US$876.00k Other Expenses US$40.44m Earnings -US$39.56m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.42 Gross Margin 100.00% Net Profit Margin -4,516.55% Debt/Equity Ratio 0%
How did VTGN perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/10 09:51 End of Day Share Price 2025/01/08 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Vistagen Therapeutics, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Brian Skorney Baird Lin Tsai Jefferies LLC Jason McCarthy Maxim Group
Show 4 more analysts 
